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Human tissue xenograft models are currently the
only tool for conducting in vivo analyses of intact
human tissue. The goal of the present study was to
develop reliable methods for successful generation of
short-term primary tissue xenografts from benign
and tumor-derived human prostate tissue. Primary
human prostate xenografts were established in athy-
mic nu/nu mice from eight of eight benign and five of
five prostate cancer tissues, collected from a total of
10 patients who underwent radical prostatectomy for
the treatment of prostate cancer. An average of 13
xenografts was established per specimen. Two tissue
specimens were cryopreserved for >1 month before
successful generation of prostate xenografts. After 1
month in vivo , xenograft tissues were harvested and
examined regarding: gross evidence of vasculariza-
tion; tissue morphology; proliferation; apoptosis; and
expression of androgen receptor, prostate-specific
antigen, and high molecular weight cytokeratins spe-
cific for basal cells in the prostate. Direct comparison
of the original tissue specimen and the 1-month xeno-
grafts revealed similar histology; similar apoptotic
and proliferative fractions in most cases; and compa-
rable expression levels and expression patterns of
androgen receptor, prostate-specific antigen, and
high molecular weight cytokeratins. These data dem-
onstrate that primary human prostate xenografts, be-
nign and malignant, can be established routinely
from human prostate tissue surgical specimens, and
that the xenografts maintain tissue architecture and
expression of key prostatic markers. The develop-
ment of this methodology, including the technique
for cryopreservation of human tissue, will allow mul-
tiple (successive) analyses of human prostate tissue to
be conducted throughout time using a tissue sample
derived from a single patient; and simultaneous anal-
ysis of human prostate tissues derived from a cohort
of patients. (Am J Pathol 2001, 159:855–860)
There are few suitable animal models for prostate cancer,
because the only mammals that develop the disease with
age are dogs and primates. In 1980, Hoehn and col-
leagues1 established the PC-82 in vivo human prostate
xenograft model (PC-82); they were the first to demon-
strate that human prostate tissue could be transplanted
and maintained as a xenograft in the subcutaneous en-
vironment of immunocompromised mice. Subsequently,
a limited number of additional prostate cancer xenograft
models have been established,2–7 and have lead to sig-
nificant advancements in the study of human prostate
cancer. However, there are limitations to the use of xeno-
grafts that include the frequency and reliability with which
they can be established and the possibility that they
become mosaics of human and host tissue throughout
time. Successful growth of primary prostate cancer tissue
in nude mice has been reported in the literature, but the
percent engraftment ranges from 5% to a maximum of
60%.4,6
Prostate xenografts offer several advantages over the
use of prostate cancer cell lines. In vivo studies with
prostate cancer cell lines typically involve subcutaneous
injection of a clonal epithelial cell line or co-injection of
epithelial and stromal cells to generate tumors. However,
the histology of the tumors rarely recapitulates the histol-
ogy of the original tissue from which the cell lines were
derived, and cell lines that are not tumorigenic in vivo
cannot be analyzed in this way. In contrast, xenografts
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allow analysis of intact tissue containing all of the cell
types present in the prostate (basal cells, epithelial cells,
stromal cells, endothelial cells, neuroendocrine cells)
within an intact tissue microenvironment, and benign tis-
sue can be compared in vivo alongside tumor tissue.
The goal of this study was not to generate additional
prostate cancer xenografts for serial passage in vivo, but
to develop a technique that would allow for reproducible
engraftment of benign and tumor-derived human pros-
tate tissue in athymic nude mice. We have established a
protocol that allows fresh, or previously cryopreserved,
benign and tumor-derived human prostate tissue trans-
planted into the subcutaneous environment of male mice
to become vascularized and remain morphologically sim-
ilar to the original tissue, maintaining similar histology,
apoptotic rate, and proliferative rate. This model repre-
sents a novel tool for the study of prostate cancer, be-
cause specimens can be collected from multiple pa-
tients, cryopreserved, and used to conduct controlled in
vivo studies in hosts that can be manipulated experimen-
tally. Potential therapeutic approaches can be evaluated
in vivo in a large cohort of benign and tumor-derived
human prostate tissues, thus providing a more reliable




Three-month-old athymic male mice (Hsd: athymic nude/
Nu) were purchased from Harlan Sprague-Dawley (Indi-
anapolis, IN). Serum testosterone levels were maintained
at 4 ng/ml by subcutaneous implantation of 12.5 mg
sustained-release testosterone pellets (Innovative Re-
search of America, Sarasota, FL). All experiments involv-
ing laboratory animals were performed in accordance
with the National Institutes of Health guidelines and ap-
proved by the Institutional Animal Care and Use Commit-
tee at the University of North Carolina in Chapel Hill.
Tissue Harvest, Cryopreservation, and
Implantation
Human prostate tissue, designated as excess tissue, was
obtained from 10 patients at the time of prostatectomy. All
tissues were collected in accordance with National Insti-
tutes of Health guidelines on the use of human subjects,
with approval by the Internal Review Board of the Univer-
sity of North Carolina Hospitals. Whenever possible, both
benign and tumor tissue were collected from an individ-
ual patient, based on gross morphological assessment of
tumor margins by the surgeon (JLM). Subsequent histo-
logical analysis of the collected tissues by a urological
pathologist (SJM) allowed each specimen to be defined
as benign (B) or tumor (T). A total of eight tissues were
defined histologically as benign, and five defined as tu-
mor. Tissue was harvested aseptically and immediately
submerged in ViaSpan organ preservation solution (Du-
Pont, Wilmington, DE) on ice. Tissue samples were cut
into wedge-shaped pieces 3 to 4 mm in length and
2-mm thick at the broadest end. Wedges were either
transplanted immediately into athymic nu/nu mice or
cryopreserved in a solution consisting of prostate growth
media8 and 10% dimethyl sulfoxide. Wedges were
thawed on ice and rinsed 3 in sterile ViaSpan before
transplantation. For transplantation, small (3 mm) slits
were made in the skin of the right and left flank of a nude
mouse anesthetized with Domitor, and one wedge of
tissue per flank was dipped in Matrigel and inserted
subcutaneously. Wounds were closed with tissue glue.
Mice were observed weekly after tissue implantation.
Tissue Evaluation
One month after implantation, mice were euthanized and
the tissue harvested to evaluate engraftment. Tissue
pieces were removed, formalin-fixed, paraffin-embed-
ded, and subjected to hematoxylin and eosin (H&E) his-
tological analysis. Proliferation was assessed in the tissue
preparations by detection of Ki67 using MIB-1 monoclo-
nal antibodies (Immunotech via Beckman Coulter, Inc.,
Fullerton, CA), and apoptosis was evaluated with the
ApopTag kit (Intergen, Purchase, NY) using the manu-
facturer’s instructions. Percentages of proliferating and
apoptotic cells were established by counting the number
of MIB-1 or ApopTag-labeled nuclei in three 400 micro-
scopic fields for each tissue. At least 2000 cells were
counted per specimen, and the numbers shown repre-
sent the average from three counts. Expression of andro-
gen receptor (AR) and prostate-specific antigen (PSA)
was evaluated with anti-AR antibodies (Biogenex, San
Ramon, CA) and anti-PSA antibodies (DAKO, Carpinte-
ria, CA). Benign tissue was confirmed by the presence of
basal cells that were identified with anti-345E12 anti-
bodies (Enzo Diagnostics, Farmingdale, NY) that detect
high molecular weight cytokeratins (HM-CK).
Results
Successful Establishment of Short-Term Benign
and Tumor Prostate Xenografts
Human prostate tissue was obtained from 10 patient
specimens, with both benign and tumor tissue taken
whenever possible. A total of eight benign and five tumor
specimens were used. One hundred percent of the spec-
imens (eight of eight benign and five of five tumor) re-
mained engrafted successfully 1 month after transplan-
tation (representative cases are shown in Figure 1). The
average number of wedges transplanted per patient
specimen was 13  1.3, and the average percent viable
at the time of harvest was 100%. Specimens 4B and 4T
were cryopreserved for 1 month before transplantation.
At the time of removal from the mouse host, two to three
macroscopic subcutaneous host vessels were con-
nected to the xenograft tissues. In most cases, the pa-
thologist’s histological evaluation of the 1-month xeno-
graft was similar or identical to the histological evaluation
of the original patient tissue specimen (Table 1). Minor
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histological differences included inflammation (10B),
squamous metaplasia (2T, 3B), and transitional metapla-
sia (1B). Tumor tissues showed identical Gleason’s
scores in the original patient tissue and the matched
xenografts.
Immunohistochemical analysis with anti-Ki67 antibod-
ies and ApopTag analysis revealed that the numbers of
proliferating and apoptotic cells seemed similar between
matched original patient tissue and 1-month xenografts
(Figure 2A). Quantitative analysis of the Ki67() and
Figure 1. Histological features of original tissues and corresponding 1-month xenograft tissues are similar, as shown by H&E analysis of representative cases. A:
Low-power images (original magnifications, 1000) were composed so that overall tissue architecture may be evaluated. B: Composed of higher power images
(original magnifications, 2000) for observation of cellular features. Although the majority of glands within each xenograft recapitulated the original tissue, some
xenografts contained isolated glands characterized by transitional cell metaplasia (1B) or squamous cell metaplasia (2B, 2T, 3B). Basal cell hyperplasia was also
a common feature of the benign xenografted tissues.
Table 1. Original Patient Prostate Tissues and Corresponding 1-Month Xenograft Tissues Were Evaluated Histologically by a
Urological Pathologist and Identified as Benign Prostate or Prostate Cancer (CaP)
Sample no. Pathology evaluation of original tissue Pathology evaluation of 1-month xenograft
1B Benign prostate Benign prostate with some transitional metaplasia
2B Benign prostate Benign prostate with some squamous metaplasia
2T CaP* (Gleason grade 6, some benign
glands present)
CaP (Gleason grade 6)/some benign glands
present; with some squamous metaplasia
3B Benign prostate Benign prostate with some squamous metaplasia
3T CaP (Gleason grade 6) CaP (Gleason grade 6)
4B Benign prostate Benign prostate
4T CaP (Gleason grade 8) CaP (Gleason grade 8)
5T CaP (Gleason grade 6) CaP (Gleason grade 6)
6B Benign prostate Benign prostate
7B Benign prostate Benign prostate
8T CaP (Gleason grade 8) CaP (Gleason grade 8)
9B Benign prostate Benign prostate
10B Benign prostate Benign prostate with inflammation
*CaPs were further characterized by the assignment of a Gleason grade.
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ApopTag() cells in matched original and xenograft tis-
sues found statistically significant differences in prolifer-
ative indices in 4 of 10 cases, and a significant difference
in apoptotic index in one case (Figure 2B). In general,
proliferation was slightly higher and apoptosis slightly
lower in the 1-month xenograft compared to the original
tissue. Immunodetectable AR protein levels were compa-
rable between original tissues and matched xenografts,
with respect to both the staining intensity and the staining
pattern (Figure 3). The original tissues and matched
xenografts were characterized further regarding the ex-
pression of PSA and basal cell-specific HM-CK. Benign
tissues and xenografts were characterized by expression
of PSA by the differentiated tall columnar luminal epithe-
lial cells and expression of HM-CK by basal cells (Figure
4). CaP tissues and xenografts were characterized by
heavy expression of PSA by glandular epithelium and the
absence of HM-CK() basal cells (Figure 4).
Discussion
Few animal models exist in which experiments can be
conducted in viable benign and cancer tissue derived
from the same human host. Animal models often do not
recapitulate human diseases accurately, and many dy-
namic questions cannot be answered by studying archi-
val human tissue specimens. The establishment of long-
term, propagable, in vivo xenograft models of human
prostate cancer (such as CWR22) represents a signifi-
cant advancement in the tools available for the study of
prostate cancer. However, it is not clear whether the
native human tissue architecture remains stable through-
out serial xenograft passage in vivo. The goal of this study
Figure 2. Apoptosis and proliferation were evaluated in the original tissues and corresponding 1-month xenograft tissues. Representative samples are shown in
A. The percentages of Apoptag-labeled cells (dark-brown nuclei) were equivalent in 9 of 10 matched original and xenograft tissues (B). Proliferative cells, as
identified by antibodies to Ki67 (dark-brown nuclear staining), were detected in matched original and xenograft tissues. The proliferative fraction was significantly
higher in 3 of 10 xenografts when compared to matched original tissue, and was significantly lower in one xenograft.
Figure 3. Original tissues and corresponding 1-month xenografts were char-
acterized regarding AR expression. Representative samples are shown. Be-
nign original tissues and xenografts were characterized by moderate AR
positivity in the nuclei of secretory epithelial cells. CaP tissues and xenografts
were characterized by a more heterogeneous expression of AR by epithelial
cells. In each case, AR staining intensity and expression pattern of the original
tissue were recapitulated in the 1-month xenograft.
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was not to generate additional long-term prostate cancer
xenografts for serial passage in vivo, but to establish
reliable methods by which primary human prostate-tissue
specimens could be used as a source of human tissue for
routine establishment of short-term subcutaneous xeno-
grafts. Although there are several valid concerns about
the use of xenograft models, including the effects of host
cells on interspecies transplants,9 they are currently the
only experimental mechanism for studying normal biol-
ogy and disease pathogenesis in intact human tissues.
The use of short-term primary xenografts generated from
patient material may offer an advantage regarding host
cell infiltration, because the opportunity for ingrowth of
host cells increases with serial passage in vivo. Our data
show clearly that it is possible to achieve 100% engraft-
ment of benign prostate tissue and prostate cancer tissue
using the methodology described in this report. The effi-
ciency with which our short-term xenografts remain viable
is much higher than the efficiencies reported in the liter-
ature by others. Factors that may contribute to the differ-
ence include: 1) immediate placement in Viaspan solu-
tion after surgical removal; 2) maintenance of the tissue at
4°C until transplantation; and 3) consistency in size and
shape of transplanted tissue. We hypothesize that nutri-
ents are able to enter the newly-transplanted tissue
wedges through simple diffusion at the tapered end,
which facilitates survival until the development of vascu-
lar connections with the host. As demonstrated in Figures
1 to 4, the tissue morphology; levels of apoptosis and
proliferation; and expression of AR, PSA, and basal cell-
specific cytokeratins, are very similar between the origi-
nal patient tissue and the matched established xenograft.
It is obvious in the H&E-stained sections that the xeno-
grafts are not necrotic or fibrotic, and vascularization is
evidenced by the presence of small vessels and red
blood cells. Thus, these methods provide a means of
tissue homeostasis; the proliferation/apoptotic rates re-
capitulate the original tissue. An additional advantage to
this short-term xenograft model is the persistence of the
prostate tissue architecture during in vivo culture. The
importance of stromal-epithelial interaction in the prostate
is well documented, and stromal cells are key in regulat-
ing differentiation of prostate epithelial cells, possibly
through AR-mediated events. Furthermore, there is am-
ple evidence to suggest that stromal cells play an active,
rather than passive, role in prostate carcinogenesis.10–14
This is reflected in the observation that the HUNC-E pros-
tate tumor epithelial cell line requires co-inoculation of a
prostate stromal cell line for tumor development in vivo.8
Models in which tissue is minced finely or cell slurries are
prepared from heterogeneous human prostate cancer
tissue offer an alternative to the injection of clonogenic
cell lines, but re-establishment of tissue architecture, par-
ticularly glandular structures, from such suspensions is
limited. By inserting an intact piece of tissue, the archi-
tecture of the glands is preserved, as well as the spatial
Figure 4. Expression of PSA and basal cell-specific cytokeratins (HM-CK) were evaluated in the original tissues and matched 1-month xenograft tissues.
Representative samples are shown. Benign prostate tissues and xenografts (6B, 10B) were characterized by expression of PSA by the secretory epithelial cells (SC)
(dark-brown to black cytoplasmic staining), and distinct expression of HM-CK by the basal cells (BC) lining the glandular structures (brown cytoplasmic staining).
Original CaP tissues and corresponding xenografts (8T) were characterized by strong PSA expression by epithelial cells, and a lack of HM-CK () basal cells.
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relationship between the stromal and epithelial cell com-
partments.
In summary, the methods outlined in this report will
enable researchers to establish in vivo xenograft cultures
from human prostate specimens with great efficiency.
The ability to cryopreserve the tissue before transplanta-
tion increases the flexibility of the model significantly and
allows for more experimental control. As shown in Figure
1, the histology of benign and tumor-derived human pros-
tate tissue is preserved in the xenografts, even when the
tissue was cryopreserved before transplantation (see
samples 4B and 4T). Using the techniques described in
this report, it will be possible to generate mice bearing
multiple xenografts derived from different patient sam-
ples, so that experiments can be conducted in a large
cohort of patient tissues using just a few mice. Likewise,
mice can be generated that contain multiple xenografts
from the same specimen, allowing grafts to be sequen-
tially harvested for analysis at multiple time points during
an experiment. For example, the in vivo response of be-
nign and tumor-derived human prostate tissue can be
evaluated after modulation of host hormone levels or
treatment with anti-cancer compounds; efficacy can be
evaluated in multiple patient tissues simultaneously, and
tissue can be analyzed at multiple time points using a
small number of animals. Furthermore, these methods for
successful engraftment of prostate tissue in vivo may be
useful in establishing xenografts of a wide variety of
human tissues, normal and diseased.
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